AstraZeneca (NYSE:AZN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell?

AstraZeneca Plc (NYSE:AZN – Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $180.13 and traded as low as $178.29. AstraZeneca shares last traded at $178.7850, with a volume of 2,537,790 shares.

Analysts Set New Price Targets

AZN has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Citigroup reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Royal Bank Of Canada began coverage on AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating on the stock. CICC Research initiated coverage on AstraZeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 target price on the stock. Finally, Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

View Our Latest Analysis on AstraZeneca

AstraZeneca Trading Down 0.7%

The company has a 50 day simple moving average of $170.72 and a 200 day simple moving average of $180.02. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.79 and a current ratio of 1.01. The company has a market capitalization of $270.17 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24.

AstraZeneca (NYSE:AZN – Get Free Report) last announced its earnings results on Saturday, October 31st. The company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. The business had revenue of $16.21 billion during the quarter, compared to analysts’ expectations of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The business’s revenue was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.38 earnings per share. Analysts anticipate that AstraZeneca Plc will post 10.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AZN. Bruce G. Allen Investments LLC boosted its stake in AstraZeneca by 9.0% during the 3rd quarter. Bruce G. Allen Investments LLC now owns 690 shares of the company’s stock worth $111,000 after purchasing an additional 57 shares during the last quarter. Aries Wealth Management raised its position in shares of AstraZeneca by 1.3% in the third quarter. Aries Wealth Management now owns 4,546 shares of the company’s stock valued at $741,000 after buying an additional 60 shares during the last quarter. Triumph Capital Management raised its position in shares of AstraZeneca by 32.6% in the third quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after buying an additional 62 shares during the last quarter. Claro Advisors Inc. raised its position in shares of AstraZeneca by 5.2% in the third quarter. Claro Advisors Inc. now owns 1,247 shares of the company’s stock valued at $201,000 after buying an additional 62 shares during the last quarter. Finally, Davis Investment Partners LLC raised its position in shares of AstraZeneca by 3.4% in the third quarter. Davis Investment Partners LLC now owns 1,868 shares of the company’s stock valued at $302,000 after buying an additional 62 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

About AstraZeneca

(Get Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

See Also

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.